Study guide

14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites

Key Takeaways Explain This Topic AI

Timing intervals for a new primary differ by module: head and neck more than 5 years, kidney and urinary more than 3 years, Other Sites more than 1 year, and melanoma more than 60 days apart; the CNS modules have no disease-free timing rule.

Tumors on both sides of a paired site are multiple primaries in head and neck (M5), kidney (M5) and melanoma (different laterality, M4), but bilateral nephroblastomas, bilateral vestibular schwannomas and bilateral retinoblastoma are single primaries.

Multiple urothelial carcinomas of the bladder, and urothelial carcinomas in several urinary organs, are generally a single primary; micropapillary plus conventional urothelial carcinoma is two primaries (urinary M8).

A glioblastoma after a glial tumor is a new primary (malignant CNS M7), multiple cranial meningiomas are one primary (non-malignant CNS M10), and a malignant CNS tumor after a resected non-malignant tumor is a new primary (non-malignant CNS M6).

Other Sites: prostate acinar adenocarcinoma is always one primary (M3), Kaposi sarcoma and retinoblastoma are always one primary, and bilateral epithelial ovarian tumors within 60 days are a single primary (M9).

Last updated: September 2026

Timing at a glance

  • Module Disease-free interval for a new primary Rule
  • Head and neck More than 5 years M6
  • Kidney More than 3 years M6
  • Renal pelvis, ureter, bladder, other urinary More than 3 years M10
  • Cutaneous melanoma Melanomas diagnosed more than 60 days apart M7
  • Other Sites More than 1 year M12
  • Malignant and non-malignant CNS No disease-free timing rule –

Remember that the rules are hierarchical: an earlier rule, such as a site-code or laterality rule, can decide a case before the timing rule is reached.

Head and neck (M1–M13)

M3: multiple primaries for tumors in any two listed site pairs, for example the aortic body and carotid body, or two different subsites of the larynx (glottis, supraglottis, subglottis, laryngeal cartilage). The module lists other subsite pairs as well.

M4: sites that differ at the 2nd or 3rd character, giving multiple primaries.

M5: tumors on both the right and left side of a paired site , for example both parotid glands, giving multiple primaries.

M6: a new tumor after more than 5 years disease-free, giving multiple primaries.

M7/M8: different subtypes or different rows in the site tables, giving multiple primaries (timing irrelevant).

M9–M11: in situ and invasive combinations. An invasive tumor more than 60 days after in situ is a new primary.

M12: same site, same row, giving a single primary.

Kidney (M1–M13)

M3: codes differ at the 2nd, 3rd or 4th character, giving multiple primaries.

M4: bilateral nephroblastomas (Wilms tumors) are a single primary, whether diagnosed together or years apart.

M5: tumors in both kidneys (other than nephroblastoma) are multiple primaries.

M6: more than 3 years disease-free, giving a new primary.

M7–M9: histology table rules. Synchronous tumors on the same row in the same kidney are a single primary (M8).

Renal pelvis, ureter, bladder and other urinary (M1–M18)

Urothelial carcinoma tends to be multifocal throughout the urinary tract, so several rules make it one primary:

M3/M4: tumors in both renal pelves , or both ureters , with no other urinary site involved, are multiple primaries.

M5: synchronous flat in situ urothelial carcinoma (8120/2) in the bladder and one or both ureters , with no other urinary organ involved, is a single primary (coded to bladder by default).

M6: invasive more than 60 days after in situ is multiple primaries.

M7: multiple occurrences of in situ (/2) urothelial carcinoma in the bladder , either flat (8120/2) or noninvasive papillary (8130/2), are a single primary, whatever the timing. Only one /2 urothelial bladder primary is abstracted in a patient's lifetime.

M8: micropapillary urothelial carcinoma 8131/3 and conventional or papillary urothelial carcinoma (8120/3, 8130/3), in any urinary sites, are multiple primaries.

M9: multiple invasive urothelial carcinomas of the bladder are a single primary.

M10: more than 3 years disease-free, giving a new primary.

M11: urothelial carcinomas in multiple urinary organs (except micropapillary) are a single primary.

Malignant CNS and peripheral nerves (M1–M14)

M3/M4: a recurrence of an oligodendroglioma with new features, or a glioma NOS recurring with a more specific histology, is a single primary.

M5: a single tumor first diagnosed as non-malignant and managed with active surveillance that becomes malignant is a single primary (the malignant).

M6: a malignant /3 CNS tumor and a non-malignant /0 or /1 CNS tumor are multiple primaries.

M7: a glial tumor followed by glioblastoma (9440) is multiple primaries .

M8: separate brain tumors with the same histology (multicentric or multifocal, any lobe or side) are a single primary.

M9: tumors in any brain lobe and another part of the CNS (for example, the spinal cord or cauda equina) are multiple primaries.

Non-malignant CNS (M1–M15)

M4: a benign /0 tumor that transforms to borderline /1 is a single primary.

M6: a malignant tumor after a resected non-malignant tumor, or when resection status is unknown, is multiple primaries. Compare M3, the active-surveillance case, which is a single primary.

M7: bilateral vestibular schwannomas (9560/0) or bilateral optic gliomas/pilocytic astrocytomas (9421/1) are a single primary.

M10: two or more meningiomas of the cranial meninges are a single primary, whatever the laterality.

M11: same-histology brain tumors are a single primary.

Cutaneous melanoma (M1–M8, 2021+)

M3: melanomas in sites that differ at the 2nd, 3rd or 4th character are multiple primaries. For example, skin of the trunk C445 and skin of the upper limb C446 are two primaries. This rule also applies to a melanoma of unknown primary plus a known cutaneous primary.

M4: different laterality gives multiple primaries.

M5: different subtypes, such as nodular and epithelioid cell melanoma, give multiple primaries.

M6: synchronous tumors on the same row with the same site code are a single primary.

M7: melanomas diagnosed more than 60 days apart are multiple primaries. This includes in situ after invasive, and invasive after in situ.

Other Sites (M1–M21, 2023+)

  • Rule Outcome
  • M3 Prostate acinar adenocarcinoma is always a single primary
  • M4 Small cell carcinoma of the prostate more than 1 year after acinar adenocarcinoma is multiple primaries
  • M5 / M6 Retinoblastoma (unilateral or bilateral) and Kaposi sarcoma (any sites) are always a single primary
  • M7 Papillary and follicular thyroid tumors diagnosed within 60 days are a single primary
  • M8 Anaplastic thyroid carcinoma plus any other thyroid histology is multiple primaries
  • M9 Bilateral epithelial ovarian tumors within 60 days are a single primary
  • M10 Tumors on both sides of a site listed in Table 1 (paired sites) are multiple primaries

M11 Adenocarcinoma in familial adenomatous polyposis is a single primary (small bowel and other sites in this module)

M12 More than 1 year disease-free is a new primary

M13 / M14 Site codes differ at the 2nd or 3rd character, giving multiple primaries. A 4th-character difference gives multiple primaries only for listed sites such as the anus and anal canal

  • M20 Invasive more than 60 days after in situ is multiple primaries
  • Histology rules: patterns that repeat across modules

A tumor with in situ and invasive parts: code the invasive histology.

NOS plus a subtype: code the subtype when it is documented under the priority rules. When a subtype is described only with an ambiguous term, the conditions in Section 13.3 apply.

Combination tables: use a combination code only when the module's table lists it, for example breast duct and lobular carcinoma 8522.

Many modules have a " last resort " rule. Before using it, confirm that no earlier rule applies.

Loading diagram... Bilateral tumors: single or multiple?